9:00 am Chair’s Opening Remarks

Modelling Patient Level Responses To Cancer Therapeutics

9:10 am Application of Patient-Derived Organoid Cultures as Preclinical Model Systems for Target Validation & Translational Research

  • Karsten Boehnke Oncology TME & Translational Research, Eli Lilly and Company

Synopsis

  • Application of patient-derived organoid cultures as preclinical model systems for target validation and translational research
  • Establishment of organoid cultures as drug testing systems; target validation studies in organoid cultures; pharmacogenomic analysis for patient population strategies

9:40 am 3D Technologies for Advanced Cancer Models

Synopsis

  • Three-dimensional (3D) cell culture models offer many advantages over more traditional 2D cell models particularly in modeling the tumor microenvironment
  • We will highlight several 3D cancer model applications that have been developed to better capture the complexity of the tumor microenvironment in assaycompatible formats/li>

9:55 am Morning Refreshment Break

10:55 am Laser Printed 3D Tissues for Oncology Studies

Synopsis

  • How Ultrafast laser based production of tissue structures works
  • Development of rapid true 3D cell Assays for Oncology using 3D Tissue Blanks
  • Early transplantation results in the nude mouse setting

11:10 am Patient-Derived Organoids for development and discovery of Oncology and Immuno-Oncology Drugs

  • Sylvia Boj Director - Scientific & Group Leader , Hubrecht Organoid Technology

Synopsis

  • Exploring how in-vitro response of organoids directly correlates with the clinical outcome of the patient
  • Showcasing the establishment of patient-derived organoids suitable for performing large scale screens
  • Highlighting the development of a novel system that allows the co-culture of organoids with immune cells to study the effect of immune modulating drugs

11:40 am Fireside Chat: Are PDO’s The New PDX?

  • Karsten Boehnke Oncology TME & Translational Research, Eli Lilly and Company
  • Sylvia Boj Director - Scientific & Group Leader , Hubrecht Organoid Technology

Synopsis

  • What lessons from PDX can be applied to PDO’s?
  • How can the immune and stromal components be best incorporated into these models?
  • In what context do PDO’s hold the most value?

12:10 pm Lunch Break

3D High-Content Screening & Analysis For Cancer Drug Discovery

1:10 pm Active-Learning Strategies for High Content Screening to Improve Clinical Relevance of Oncology Therapeutics

Synopsis

  • Introducing novel 3D tumor in vitro models, high content imaging and cell-based screening technologies improving clinical relevance in the testing of oncology drugs
  • Showcasing the design and build of an intelligent, automated platform to accelerate the identification of high value small molecule leads, and the delivery of quality candidates into clinical development
  • Discussing computational active-learning approaches used in high content screenings of a large number of 3D tumor spheroid images

1:40 pm KEYNOTE: Combined Genetic Analysis and 3D Screening of Approved Drugs Directly on GBM Patient Tumors

  • Tim Spicer Senior Associate Director - Scientific & Molecular Medicine , Scripps Institute

Synopsis

  • Showcasing a fully automated 1536 well compatible platform able to perform HTS on large compound libraries
  • Highlighting the applicability of 3D spheroid based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology

2:10 pm Industrialized 3D Drug Discovery: Spheroids in 1536-well Format

Synopsis

  • Understanding how to overcome late stage failures by adopting novel screening strategies using complex 3D platforms in HTS environments
  • Utilizing organotypic systems to better enable targeting and modulation of intended mechanisms
  • Employing novel technologies to translate better performing drug candidate selection early on

2:40 pm Summary Panel Discussion – Assessing Where 3D Systems Shine in Discovery

  • Shane Horman Research Investigator III , Novartis GNF
  • Alejandro Amador Head, Scientific Leader Discovery Biology Automation, GSK
  • Tim Spicer Senior Associate Director - Scientific & Molecular Medicine , Scripps Institute

Synopsis

  • Does the value of 3D lie with HTS or HCS? Phenotypic or Target Based Screening?
  • Justifying risk: Where do we envisage the technology heading and what can these systems never do?
  • How should we weigh up the cost per data point against the importance of throughputness?
  • Should we compromise the predictive value of models because of assay cost, throughput, convenience and use?

3:10 pm Chair’s Closing Remarks

3:15 pm Close of Conference